CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing novel nucleic acid therapeutics for orphan diseases, today announced that Company management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at 8:30 a.m. EDT in New York City.
A live audio webcast of the presentation will be available in the Investors and Media section of Idera’s website at www.iderapharma.com or at the link http://wsw.com/webcast/jeff82/IDRA. An archived version will also be available on the Company’s website after the event for 90 days.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases. Idera’s proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.